<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01024686</url>
  </required_header>
  <id_info>
    <org_study_id>WR 1584</org_study_id>
    <nct_id>NCT01024686</nct_id>
  </id_info>
  <brief_title>Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine</brief_title>
  <official_title>Phase 1/2a Trial to Assess the Safety, Immunogenicity and Efficacy of Genetically-attenuated Plasmodium Falciparum Parasites p52-/p36- (GAP) Vaccine, Administered by Bite of Infected Anopheles Mosquito to Malaria-naïve Adults Living in the United States.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Children’s Research Institute (SCRI)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Children’s Research Institute (SCRI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety and tolerability of escalating doses of a
      genetically attenuated parasite malaria vaccine (p52-/p36- GAP vaccine) in healthy
      malaria-naive adults. The study will also assess preliminary efficacy of p52-/p36- GAP
      vaccine following primary experimental challenge with P. falciparum sporozoites. Lastly, the
      study will assess immunogenicity of p52-/p36- GAP in malaria-naïve healthy adults and
      preliminary efficacy of p52-/p36- GAP vaccine following primary experimental re-challenge
      with P. falciparum sporozoites.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Solicited Adverse Events (AE)</measure>
    <time_frame>From administration of study vaccine through 7 days (± 1 days) post dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Unsolicited AEs</measure>
    <time_frame>From administration of study vaccine through 28 days (± 4 days) post dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Laboratory Adverse Events (AE)</measure>
    <time_frame>From administration of study vaccine through 7 days (± 1 days) post dosing</time_frame>
    <description>Volunteers with any laboratory abnormality.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection of Breakthrough Peripheral Parasitemia by Thick Blood Film</measure>
    <time_frame>From 7 days after administration of vaccine through 28 days (+ 4 days) post-dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Serious Adverse Events (SAE)</measure>
    <time_frame>baseline through 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of Parasitemia and Time to Parasitemia After Primary Malaria Challenge Following Administration of GAP</measure>
    <time_frame>From administration of study vaccine through the duration of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Parasitemia and Time to Parasitemia After Re-challenge Following Administration of GAP</measure>
    <time_frame>From administration of study vaccine through the duration of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P. Falciparum Specific Cell-mediated Immune Responses</measure>
    <time_frame>From administration of study vaccine through the duration of the trial</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>p52-p36- GAP Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>p52-/p56- GAP Vaccine: Administered by five bites from GAP-infected Anopheles mosquito.
p52-/p56- GAP Vaccine: Administered by 200 bites from GAP-infected Anopheles mosquito.
Challenge: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infectivity Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Active Control: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>p52-p36- GAP Vaccine + Infectivity Challenge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>p52-/p36- GAP Vaccine: Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito.
Challenge: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>p52-/p36- GAP Vaccine</intervention_name>
    <description>Administered by five bites from GAP-infected Anopheles mosquito</description>
    <arm_group_label>p52-p36- GAP Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>p52-p36- GAP Vaccine</intervention_name>
    <description>Administered by 200 bites from GAP-infected Anopeles mosquito</description>
    <arm_group_label>p52-p36- GAP Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>p52-/p36- GAP Vaccine</intervention_name>
    <description>Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito</description>
    <arm_group_label>p52-p36- GAP Vaccine + Infectivity Challenge</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or non-pregnant, non-lactating female 18 to 50 years of age (inclusive) at the
             time of enrollment

          -  Free of significant health problems as established by medical history, laboratory
             assessment and clinical examination before entering into the study

          -  Volunteers must have low cardiac risk factors according to the NHANES I criteria and a
             non-significant electrocardiogram (EKG) as determined by a expert consultant
             cardiologist

          -  Available to participate for duration of study

          -  Reproductive status: a female participant must:

          -  not be of reproductive potential: i.e. be surgically, medically or physiologically
             sterile, or

          -  if engages in sexual activity that could lead to pregnancy:

          -  agrees to consistently use contraception until 2 months after the last protocol visit.
             Contraception is defined as using 1 of the following methods:

          -  condoms (male or female) with or without a spermicide

          -  diaphragm or cervical cap with spermicide

          -  intrauterine device (IUD)

          -  hormonal contraception

          -  If the volunteer indicates he/she is active duty military (on the DCT sign-in page and
             intake form), approval from their supervisor through the Division Director using the
             Statement of Supervisor's Approval Form must be signed and on file prior to receipt of
             any test product

          -  Written informed consent must be obtained from the subject before screening procedures

          -  Prior to entry into this study, subjects must score at least 80% correct on a 10-
             question multiple-choice quiz that assesses their understanding of this study.

        Exclusion Criteria:

          -  Prior receipt of any investigational malaria vaccine

          -  Use of any investigational or non-registered drug or vaccine other than the study
             vaccine within 30 days preceding the first dose of study vaccine, or planned use
             during the study period

          -  Administration of any vaccine within 30 days of first study vaccination Any past
             history of malaria

          -  Planned travel to malarious areas during the study period

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             human immunodeficiency virus (HIV) infection

          -  A family history of congenital or hereditary immunodeficiency

          -  Moderate or high 5-year cardiovascular risk as determined by NHANES 1 model

          -  An abnormal 12-lead electrocardiogram (EKG) suggestive of cardiac disease as
             determined by a clinician

          -  Seropositive for HIV, Hepatitis C virus (antibodies to HCV) and/or HBsAg

          -  Hepatomegaly, right upper quadrant abdominal pain or tenderness

          -  History of splenectomy

          -  Chronic or active neurologic disease including seizure disorder and chronic migraine
             headaches

          -  History of psoriasis and porphyria

          -  Acute or chronic, clinically significant pulmonary, cardiovascular, ocular,
             hematologic, hepatic or renal functional abnormality, as determined by physical
             examination or abnormal baseline laboratory screening tests and medical history review

          -  Administration of chronic (defined as more than 14 days) immunosuppressants or other
             immune-modifying drugs within six months of vaccination. For corticosteroids, this is
             defined as prednisone, or equivalent, 0.5 mg/kg/day. Inhaled and topical steroids are
             allowed.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the first dose of study vaccine or planned administration during the study
             period

          -  Current chronic use of medications known to cause drug reactions with chloroquine
             and/or atovaquone/proguanil such as cimetidine and metoclopramide.

          -  Current chronic use or use within one month prior to enrollment of antibiotics with
             anti-malarial effects such as tetracyclines for acne, sulfa drugs for recurrent
             urinary tract infections, etc.

          -  Pregnant or lactating female

          -  Female who is willing or intends to become pregnant during the study and for two (2)
             months after study completion

          -  Any history of allergic reaction or anaphylaxis to previous vaccination

          -  History of severe reactions to mosquito bites.

          -  Inability to make follow-up visits or complete diary cards

          -  Suspected or known current alcohol abuse/drug abuse as obtained by history and
             physical examination

          -  Any other significant finding that in the opinion of the investigator would increase
             the risk of having an adverse outcome from participating in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Spring, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed Army Institute of Research (WRAIR)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Reed Army Institute of Research</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/24029408</url>
    <description>First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers.</description>
  </link>
  <results_reference>
    <citation>Spring M, Murphy J, Nielsen R, Dowler M, Bennett JW, Zarling S, Williams J, de la Vega P, Ware L, Komisar J, Polhemus M, Richie TL, Epstein J, Tamminga C, Chuang I, Richie N, O'Neil M, Heppner DG, Healer J, O'Neill M, Smithers H, Finney OC, Mikolajczak SA, Wang R, Cowman A, Ockenhouse C, Krzych U, Kappe SH. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine. 2013 Oct 9;31(43):4975-83. doi: 10.1016/j.vaccine.2013.08.007. Epub 2013 Sep 8.</citation>
    <PMID>24029408</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>December 1, 2009</study_first_submitted>
  <study_first_submitted_qc>December 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2009</study_first_posted>
  <results_first_submitted>June 18, 2019</results_first_submitted>
  <results_first_submitted_qc>October 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 28, 2019</results_first_posted>
  <last_update_submitted>October 4, 2019</last_update_submitted>
  <last_update_submitted_qc>October 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>p52-p36- GAP Vaccine</title>
          <description>p52-/p36- GAP Vaccine: Administered by five bites from GAP-infected Anopheles mosquito.
p52-p36- GAP Vaccine: Administered by 200 bites from GAP-infected Anopheles mosquito.
Challenge: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum.</description>
        </group>
        <group group_id="P2">
          <title>Infectivity Control</title>
          <description>Active Control: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum</description>
        </group>
        <group group_id="P3">
          <title>p52-p36- GAP Vaccine + Infectivity Challenge</title>
          <description>p52-/p36- GAP Vaccine: Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito
Challenge: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6">July 11, 2010: unexpected adverse event, (1) participant</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0">(0) participants because the clinical trial was terminated prior to enrollment.</participants>
                <participants group_id="P3" count="0">(0) participants because the clinical trial was terminated prior to enrollment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No data is available for Infectivity Control or p52-p36- GAP Vaccine + Infectivity Challenge because the clinical trial was terminated prior to enrollment.</population>
      <group_list>
        <group group_id="B1">
          <title>p52-p36- GAP Vaccine</title>
          <description>p52-/p36- GAP Vaccine: Administered by five bites from GAP-infected Anopheles mosquito.
p52-p36- GAP Vaccine: Administered by 200 bites from GAP-infected Anopheles mosquito.
Challenge: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum.</description>
        </group>
        <group group_id="B2">
          <title>Infectivity Control</title>
          <description>Active Control: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum.</description>
        </group>
        <group group_id="B3">
          <title>p52-p36- GAP Vaccine + Infectivity Challenge</title>
          <description>p52-/p36- GAP Vaccine: Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito.
Challenge: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Solicited Adverse Events (AE)</title>
        <time_frame>From administration of study vaccine through 7 days (± 1 days) post dosing</time_frame>
        <population>(0) Zero participants analyzed because the study was terminated prior to enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>p52-p36- GAP Vaccine</title>
            <description>p52-/p36- GAP Vaccine: Administered by five bites from GAP-infected Anopheles mosquito
p52-p36- GAP Vaccine: Administered by 200 bites from GAP-infected Anopheles mosquito</description>
          </group>
          <group group_id="O2">
            <title>Infectivity Control</title>
          </group>
          <group group_id="O3">
            <title>p52-p36- GAP Vaccine + Infectivity Challenge</title>
            <description>p52-/p36- GAP Vaccine: Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Solicited Adverse Events (AE)</title>
          <population>(0) Zero participants analyzed because the study was terminated prior to enrollment.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Unsolicited AEs</title>
        <time_frame>From administration of study vaccine through 28 days (± 4 days) post dosing</time_frame>
        <population>(0) Participants because clinical study was terminated before enrollment for Infectivity Control and p52-p36- GAP Vaccine + Infectivity Challenge.</population>
        <group_list>
          <group group_id="O1">
            <title>p52-p36- GAP Vaccine</title>
            <description>p52-/p36- GAP Vaccine: Administered by five bites from GAP-infected Anopheles mosquito
p52-p36- GAP Vaccine: Administered by 200 bites from GAP-infected Anopheles mosquito</description>
          </group>
          <group group_id="O2">
            <title>Infectivity Control</title>
          </group>
          <group group_id="O3">
            <title>p52-p36- GAP Vaccine + Infectivity Challenge</title>
            <description>p52-/p36- GAP Vaccine: Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Unsolicited AEs</title>
          <population>(0) Participants because clinical study was terminated before enrollment for Infectivity Control and p52-p36- GAP Vaccine + Infectivity Challenge.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Laboratory Adverse Events (AE)</title>
        <description>Volunteers with any laboratory abnormality.</description>
        <time_frame>From administration of study vaccine through 7 days (± 1 days) post dosing</time_frame>
        <population>(0) Participants because clinical study was terminated before enrollment for Infectivity Control and p52-p36- GAP Vaccine + Infectivity Challenge</population>
        <group_list>
          <group group_id="O1">
            <title>p52-p36- GAP Vaccine</title>
            <description>p52-/p36- GAP Vaccine: Administered by five bites from GAP-infected Anopheles mosquito
p52-p36- GAP Vaccine: Administered by 200 bites from GAP-infected Anopheles mosquito</description>
          </group>
          <group group_id="O2">
            <title>Infectivity Control</title>
          </group>
          <group group_id="O3">
            <title>p52-p36- GAP Vaccine + Infectivity Challenge</title>
            <description>p52-/p36- GAP Vaccine: Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Laboratory Adverse Events (AE)</title>
          <description>Volunteers with any laboratory abnormality.</description>
          <population>(0) Participants because clinical study was terminated before enrollment for Infectivity Control and p52-p36- GAP Vaccine + Infectivity Challenge</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Detection of Breakthrough Peripheral Parasitemia by Thick Blood Film</title>
        <time_frame>From 7 days after administration of vaccine through 28 days (+ 4 days) post-dosing</time_frame>
        <population>(0) Participants because clinical study was terminated before enrollment for Infectivity Control and p52-p36- GAP Vaccine + Infectivity Challenge.</population>
        <group_list>
          <group group_id="O1">
            <title>p52-p36- GAP Vaccine</title>
            <description>p52-/p36- GAP Vaccine: Administered by five bites from GAP-infected Anopheles mosquito
p52-p36- GAP Vaccine: Administered by 200 bites from GAP-infected Anopheles mosquito</description>
          </group>
          <group group_id="O2">
            <title>Infectivity Control</title>
          </group>
          <group group_id="O3">
            <title>p52-p36- GAP Vaccine + Infectivity Challenge</title>
            <description>p52-/p36- GAP Vaccine: Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito</description>
          </group>
        </group_list>
        <measure>
          <title>Detection of Breakthrough Peripheral Parasitemia by Thick Blood Film</title>
          <population>(0) Participants because clinical study was terminated before enrollment for Infectivity Control and p52-p36- GAP Vaccine + Infectivity Challenge.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Serious Adverse Events (SAE)</title>
        <time_frame>baseline through 28 days</time_frame>
        <population>(0) Participants because clinical study was terminated before enrollment for Infectivity Control and p52-p36- GAP Vaccine + Infectivity Challenge.</population>
        <group_list>
          <group group_id="O1">
            <title>p52-p36- GAP Vaccine</title>
            <description>p52-/p36- GAP Vaccine: Administered by five bites from GAP-infected Anopheles mosquito
p52-p36- GAP Vaccine: Administered by 200 bites from GAP-infected Anopheles mosquito</description>
          </group>
          <group group_id="O2">
            <title>Infectivity Control</title>
          </group>
          <group group_id="O3">
            <title>p52-p36- GAP Vaccine + Infectivity Challenge</title>
            <description>p52-/p36- GAP Vaccine: Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Serious Adverse Events (SAE)</title>
          <population>(0) Participants because clinical study was terminated before enrollment for Infectivity Control and p52-p36- GAP Vaccine + Infectivity Challenge.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Parasitemia and Time to Parasitemia After Primary Malaria Challenge Following Administration of GAP</title>
        <time_frame>From administration of study vaccine through the duration of the trial</time_frame>
        <population>(0) Participants because clinical study was terminated before enrollment for primary malaria challenge</population>
        <group_list>
          <group group_id="O1">
            <title>p52-p36- GAP Vaccine</title>
            <description>p52-/p36- GAP Vaccine: Administered by five bites from GAP-infected Anopheles mosquito
p52-p36- GAP Vaccine: Administered by 200 bites from GAP-infected Anopheles mosquito</description>
          </group>
          <group group_id="O2">
            <title>Infectivity Control</title>
          </group>
          <group group_id="O3">
            <title>p52-p36- GAP Vaccine + Infectivity Challenge</title>
            <description>p52-/p36- GAP Vaccine: Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Parasitemia and Time to Parasitemia After Primary Malaria Challenge Following Administration of GAP</title>
          <population>(0) Participants because clinical study was terminated before enrollment for primary malaria challenge</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Parasitemia and Time to Parasitemia After Re-challenge Following Administration of GAP</title>
        <time_frame>From administration of study vaccine through the duration of the trial</time_frame>
        <population>(0) Participants because clinical study was terminated before enrollment for primary malaria challenge.</population>
        <group_list>
          <group group_id="O1">
            <title>p52-p36- GAP Vaccine</title>
            <description>p52-/p36- GAP Vaccine: Administered by five bites from GAP-infected Anopheles mosquito
p52-p36- GAP Vaccine: Administered by 200 bites from GAP-infected Anopheles mosquito</description>
          </group>
          <group group_id="O2">
            <title>Infectivity Control</title>
          </group>
          <group group_id="O3">
            <title>p52-p36- GAP Vaccine + Infectivity Challenge</title>
            <description>p52-/p36- GAP Vaccine: Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Parasitemia and Time to Parasitemia After Re-challenge Following Administration of GAP</title>
          <population>(0) Participants because clinical study was terminated before enrollment for primary malaria challenge.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>P. Falciparum Specific Cell-mediated Immune Responses</title>
        <time_frame>From administration of study vaccine through the duration of the trial</time_frame>
        <population>(0) data available because the clinical trial was terminated before DAY 90 blood draw for P. falciparum specific cell-mediated immune responses.</population>
        <group_list>
          <group group_id="O1">
            <title>p52-p36- GAP Vaccine</title>
            <description>p52-/p36- GAP Vaccine: Administered by five bites from GAP-infected Anopheles mosquito
p52-p36- GAP Vaccine: Administered by 200 bites from GAP-infected Anopheles mosquito</description>
          </group>
          <group group_id="O2">
            <title>Infectivity Control</title>
          </group>
          <group group_id="O3">
            <title>p52-p36- GAP Vaccine + Infectivity Challenge</title>
            <description>p52-/p36- GAP Vaccine: Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito</description>
          </group>
        </group_list>
        <measure>
          <title>P. Falciparum Specific Cell-mediated Immune Responses</title>
          <population>(0) data available because the clinical trial was terminated before DAY 90 blood draw for P. falciparum specific cell-mediated immune responses.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>This clinical study was withdrawn before enrollment of participants for arm 2 and arm 3. Therefore, no participants were at risk for adverse events from these arms.</desc>
      <group_list>
        <group group_id="E1">
          <title>p52-p36- GAP Vaccine</title>
          <description>p52-/p36- GAP Vaccine: Administered by five bites from GAP-infected Anopheles mosquito.
p52-p36- GAP Vaccine: Administered by 200 bites from GAP-infected Anopheles mosquito.
Challenge: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum.</description>
        </group>
        <group group_id="E2">
          <title>Infectivity Control</title>
          <description>Active Control: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum.</description>
        </group>
        <group group_id="E3">
          <title>p52-p36- GAP Vaccine + Infectivity Challenge</title>
          <description>p52-/p36- GAP Vaccine: Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito
Challenge: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Peripheral parasitemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <counts group_id="E1" events="13" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="27" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Application site papules</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site discoloration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vaccination site pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal Allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pharyngeal erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="19" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Puritus</sub_title>
                <counts group_id="E1" events="18" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rash papuar</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Scab</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michele Spring</name_or_title>
      <organization>U.S. Military Malaria Vaccine Program (USMMVP)</organization>
      <phone>301-319-9307</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

